135 related articles for article (PubMed ID: 27878356)
21. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
22. LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.
Matsumoto J; Kiesel BF; Parise RA; Guo J; Taylor S; Huang M; Eiseman JL; Ivy SP; Kunos C; Chu E; Beumer JH
J Pharm Biomed Anal; 2017 Nov; 146():154-160. PubMed ID: 28881312
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
25. Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Hellmann MD; Sturm I; Trnkova ZJ; Lettieri J; Diefenbach K; Rizvi NA; Gettinger SN
Clin Lung Cancer; 2015 Nov; 16(6):514-22. PubMed ID: 26003007
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.
Bible KC; Lensing JL; Nelson SA; Lee YK; Reid JM; Ames MM; Isham CR; Piens J; Rubin SL; Rubin J; Kaufmann SH; Atherton PJ; Sloan JA; Daiss MK; Adjei AA; Erlichman C
Clin Cancer Res; 2005 Aug; 11(16):5935-41. PubMed ID: 16115936
[TBL] [Abstract][Full Text] [Related]
28. Fractionated scheme of oral vinorelbine as single-agent therapy or in combination with cisplatin concomitantly with thoracic radiotherapy in stage III non-small-cell lung cancer: dose-escalation phase I trial.
Krzakowski M; Lucas C; Gridelli C
Clin Lung Cancer; 2014 Jul; 15(4):266-73. PubMed ID: 24954229
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
30. NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.
Ellis PM; Shepherd FA; Laurie SA; Goss GD; Olivo M; Powers J; Seymour L; Bradbury PA
J Thorac Oncol; 2014 Mar; 9(3):410-3. PubMed ID: 24518092
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
32. Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
Shapiro GI; Tibes R; Gordon MS; Wong BY; Eder JP; Borad MJ; Mendelson DS; Vogelzang NJ; Bastos BR; Weiss GJ; Fernandez C; Sutherland W; Sato H; Pierceall WE; Weaver D; Slough S; Wasserman E; Kufe DW; Von Hoff D; Kawabe T; Sharma S
Clin Cancer Res; 2011 May; 17(10):3431-42. PubMed ID: 21220472
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
Bilenker JH; Stevenson JP; Flaherty KT; Algazy K; McLaughlin K; Haller DG; Giantonio BJ; Koehler M; Garcia-Vargas JE; O'Dwyer PJ
Cancer Chemother Pharmacol; 2004 Apr; 53(4):357-60. PubMed ID: 14722734
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
Mundt AJ; Rotmensch J; Waggoner SE; Yamada SD; Fleming GF
Gynecol Oncol; 2004 Mar; 92(3):801-5. PubMed ID: 14984944
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
37. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Zeidner JF; Karp JE; Blackford AL; Smith BD; Gojo I; Gore SD; Levis MJ; Carraway HE; Greer JM; Ivy SP; Pratz KW; McDevitt MA
Haematologica; 2014 Apr; 99(4):672-8. PubMed ID: 24362550
[TBL] [Abstract][Full Text] [Related]
38. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
40. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]